Skip to main content

Table 1 Number and diameter of different ovarian structures in control and ALLO treated rats along the estrous cycle

From: Allopregnanolone alters follicular and luteal dynamics during the estrous cycle

Group (cyclic stage) Control (E) ALLO (E) Control (D1) ALLO (D1) Control (D2) ALLO (D2) Control (PE) ALLO (PE)
PF (n) 3.17 ± 0.75 2.83 ± 0.75 6.50 ± 0.65 5.75 ± 0.75 6.80 ± 1.74 5.00 ± 0.77** 3.50 ± 0.43 2.60 ± 0.40
PAF (n) 3.94 ± 0.56 2.77 ± 0.33 6.25 ± 1.32 7.75 ± 1.44 8.25 ± 1.32 7.40 ± 2.48 3.17 ± 0.65 1.80 ± 0.80
EAF (n) 4.83 ± 0.31 2.83 ± 0.31** 5.25 ± 0.85 2.50 ± 0.50*** 9.20 ± 1.74 1.75 ± 2.08*** 2.50 ± 0.34 0.80 ± 0.49*
AF (n) 2.67 ± 0.33 1.33 ± 0.33* 3.50 ± 0.65 0.50 ± 0.50*** 4.40 ± 1.03 2.60 ± 1.08** 1.50 ± 0.56 1.00 ± 0.45
GF (n) 2.83 ± 0.31 0.67 ± 0.21*** 0.75 ± 0.48 0.5 ± 0.5 0.08 ± 0.02 0.80 ± 0.58 0.67 ± 0.49 0.2 ± 0.2
CL (n) 7.65 ± 2.20 6.35 ± 1.10 7.25 ± 0.85 8.25 ± 1.18 13.50 ± 0.50 9.60 ± 0.93** 6.16 ± 1.08 8.40 ± 1.33
ATF (n) 2.75 ± 1.10 4.77 ± 0.90*** 7.67 ± 1.20 11.75 ± 1.03** 5.00 ± 0.71 12.80±2.25*** 9.33 ± 0.61 12.20 ± 0.97**
Cysts (n) 2.00 ± 0.55 6.00 ± 1.33*** 0.01 ± 0.01 0.63 ± 0.26* 0.01 ± 0.01 0.63 ± 0.26* 0 0
EAF diameter (μm) 244.9 ± 19.84 208.70±14.14* 191.00 ± 21.48 189.30 ± 19.17 220.50 ± 31.65 212.80 ± 23.41 216.50 ± 25.55 234.30 ± 5.22
AF diameter (μm) 399.6 ± 26.25 413.15 ± 30.30 415.10 ± 37.51 420.80 ± 49.45 355.50 ± 37.82 378.70 ± 70.96 402.90 ± 12.97 375.00 ± 20.02
GF diameter (μm) 650.9 ± 34.03 603.62 ± 65.12 639.50 ± 20.01 646.10 ± 1.37 654.30 ± 55.29 614.30 ± 29.70 670.76 ± 32.98 689.87 ± 33.98
CL diameter (μm) 758 ± 65.01 836.30 ± 82.30 1019 ± 137.70 848 ±82.32** 946.60 ± 99.56 882.10 ± 97.88 1006 ± 66.93 999.89 ± 61.55
  1. Number of ovarian structures (n) are expressed as Mean ± S.E.M. of primary (PF), preantral (PAF), early antral (EAF), antral (AF), Graafian (GF), atretic follicles (ATF), corpora lutea (CL) and cysts (follicular and luteal cysts). Mean diameter (μm) ± S.E.M of EAF, AF, GF and CL along the estrous cycle from control and ALLO treated rats. Two-way ANOVA followed by Bonferroni’s post hoc, (n=6), ns p>0.05, *p<0.05, **p<0.01, ***p<0.001.